Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial

Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial

This study was performed to evaluate the effectiveness of ramosetron orally disintegrating tablets (ODTs) in preventing post-discharge nausea and/or vomiting (PDNV) in female patients following outpatient surgery under general anesthesia. This multicenter randomized study included three South Korean...

Full description

Saved in:
Bibliographic Details
Published in:Perioperative medicine (London) Vol. 11; no. 1; p. 17
Main Authors: Shin, Hyun-Jung, Park, Yong-Hee, Chang, Minying, Chae, Yun Jeong, Lee, Hun-Taek, Lee, Oh Haeng, Min, Sang-Kee, Do, Sang-Hwan
Format: Journal Article
Language:English
Published: England BioMed Central Ltd 12-05-2022
BioMed Central
BMC
Subjects:
Airway management
Analysis
Anesthesia
Antiemetics
Central nervous system depressants
Drug therapy
General anesthesia
Health aspects
Metoclopramide
Nausea
Outpatient care facilities
Outpatient surgery
Pain
Patient satisfaction
Performance evaluation
Post-discharge
Prokinetic agents
Ramosetron
Surgery
Surgical clinics
Vomiting
Women
South Korea
United Kingdom > UK
United States > US
Outpatient surgery
Nausea
Ramosetron
Post-discharge
Vomiting
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was performed to evaluate the effectiveness of ramosetron orally disintegrating tablets (ODTs) in preventing post-discharge nausea and/or vomiting (PDNV) in female patients following outpatient surgery under general anesthesia. This multicenter randomized study included three South Korean tertiary hospitals. Before surgery, 138 patients were randomly allocated into two groups. In the ramosetron group, ramosetron ODT 0.1 mg was administered after discharge in the morning of postoperative days 1 and 2. Metoclopramide 10 mg was administered as a rescue antiemetic (capped at 30 mg per day). In the control group, patients were administered only metoclopramide 10 mg when nausea and/or vomiting occurred. The primary outcome was the incidence of nausea during 24 h after discharge. We found significant differences in the incidence (13% vs. 33%, P = 0.008) and severity (P = 0.011) of nausea between the ramosetron and the control groups during 24 h after discharge. In addition, the rate of rescue antiemetic (metoclopramide) administration during 24 h after discharge was lower in the ramosetron group (6%) than in the control group (18%) (P = 0.033). Patient satisfaction score was higher in the ramosetron group than in the control group (P < 0.001). Ramosetron ODT reduces the incidence and severity of postoperative nausea after discharge during the first 24 h and may be a valuable option for the prevention of PDNV in female patients after day surgery under general anesthesia. ClinicalTrials.gov, NCT04297293 . Registered on 05 March 2020.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2047-0525
2047-0525
DOI:10.1186/s13741-022-00251-6